MFDS
- Status: likely_approved
Tysabri (NATALIZUMAB) regulatory status in South Korea.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MFDS has authorised it; MFDS has authorised it; MFDS has authorised it.
Biogen Idec is the originator. The local marketing authorisation holder may differ — check the official source linked above.